Business units split at French precision medicine firm
Oncodesign (Euronext: ALONC), a French biopharma group specializing in precision medicine, has announced that, as part of the planned separation of its two business areas, the board of directors has approved the subsidiarization of its Biotech unit as it splits off from the Service division.
The Biotech unit’s purpose will remain the development of new molecules dedicated to precision medicine and new targets identifiable thanks to artificial intelligence (AI). In its attempts to discover effective new treatments for cancers and other diseases where no effective therapies currently exist, the business will draw on the Nanocyclix and Oncosniper technologies as well as on an innovative technological approach linked to systemic radiotherapy.
"Each business area will be able to unleash its growth potential"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze